PRECISION RADIOTHERAPEUTICS
AND ONCOLOGY PROGRAMME
Embedded Files
About Us
About Us
Our passion and goal is to develop highly personalized forms of clinical treatment for nasopharyngeal, prostate, head and neck cancer. As every tumor has it's own unique characteristics, understanding these characteristics could help us predict the success rate of today's therapies. Utilizing bioinformatics enable us to analyze datasets, which are used to create clinical diagnostic tools for personalized therapy.
This laboratory is led by Prof Soo Khee Chee and Dr. Melvin Chua, together with individuals from a variety of research backgrounds and qualifications. This diversity brings in different talents together, all of us working towards a common goal using different skill sets.
Lab Homepage Video.mp4
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
Platinum-based concurrent chemoradiotherapy is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials.
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline
This joint guideline aims to provide evidence-based recommendations to practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma (NPC).
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial
The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma is unclear. This randomized clinical trial examines the efficacy and safety of locoregional radiotherapy vs raditherapy alone in patients with de novo metastatic nasopharyngeal carcinoma.
NEWS
NEWS
Transforming nasopharyngeal carcinoma and clinical management
Transforming nasopharyngeal carcinoma and clinical management
Comprehensive study to characterize the longitudinal changes in Epstein-Barr Virus (EBV) DNA following radiotherapy in patients diagnosed with Nasopharyngeal Carcinoma (NPC) patients. The primary aim of the investigation is to determine whether early or delayed post-radiotherapy EBV DNA testing serves as a more accurate predictor of disease-free survival in these patients. By meticulously analyzing the temporal dynamics of EBV DNA levels, this could significantly enhance the prognostic accuracy by identifying the optimal timepoint for measurement.
Find out more:
Page updated
Google Sites
Report abuse